Principles of surfactant replacement  by Robertson, Bengt & Halliday, Henry L.
Review
Principles of surfactant replacement
Bengt Robertson a;*, Henry L. Halliday b
a Division for Experimental Perinatal Pathology, Department of Woman and Child Health, Karolinska Hospital, Stockholm, Sweden
b Regional Neonatal Unit, Royal Maternity Hospital Belfast and Department of Child Health, The Queen’s University of Belfast,
Belfast, Northern Ireland, UK
Received 7 April 1998; received in revised form 21 July 1998; accepted 21 July 1998
Abstract
Surfactant therapy is an established part of routine clinical management of babies with respiratory distress syndrome. An
initial dose of about 100 mg/kg is usually needed to compensate for the well documented deficiency of alveolar surfactant in
these babies, and repeated treatment is required in many cases. Recent experimental and clinical data indicate that large
doses of exogenous surfactant may be beneficial also in conditions characterized by inactivation of surfactant, caused by, for
example, aspiration of meconium, infection, or disturbed alveolar permeability with leakage of plasma proteins into the
airspaces. The acute response to surfactant therapy depends on the quality of the exogenous material (modified natural
surfactants are generally more effective than protein-free synthetic surfactants), timing of treatment in relation to the clinical
course (treatment at an early stage of the disease is better than late treatment, and may reduce the subsequent need for
mechanical ventilation), and mode of delivery (rapid instillation via a tracheal tube leads to more uniform distribution and is
more effective than slow airway infusion). Treatment with aerosolized surfactant improves lung function in animal models of
surfactant deficiency or depletion, but is usually associated with large losses of the nebulized material in the delivery system.
Furthermore, data from experiments on immature newborn lambs indicate that treatment response may depend on the mode
of resuscitation at birth, and that manual ventilation with just a few large breaths may compromise the effect of subsequent
surfactant therapy. The widespread clinical use of surfactant has reduced neonatal mortality and lowered costs for intensive
care in developed countries. The hydrophobic surfactant proteins SP-B and SP-C are probably essential for optimal
biophysical and physiological activity of exogenous surfactants isolated from mammalian lungs, and the dose-effectiveness
(in part reflecting resistance to inactivation) can be further improved by enrichment with SP-A. The development of new
artificial surfactant substitutes, based on synthetic analogues of the native surfactant proteins, is an important challenge for
future research. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Surfactant replacement is commonly used today
in the clinical management of newborn babies
with respiratory distress syndrome (RDS), and there
is accumulating evidence indicating that this treat-
ment might also be e¡ective in several other forms
of lung disease including meconium aspiration syn-
drome (MAS), neonatal pneumonia, and the ‘adult’
form of acute respiratory distress syndrome
(ARDS). Surfactant therapy constitutes a logical ex-
tension of the classical observation that lungs of
babies dying from RDS lack surface active material
and is further based on the assumption that it
should be possible to compensate for this de¢cit
by administering the missing material (or some
equivalent substance) via the airways. The idea is
not new. It was clearly expressed as early as 1947
by an imaginative American pathologist, Peter
Gruenwald. On the basis of pressure-volume record-
ings and histological observations on lungs of ba-
bies with RDS, Gruenwald understood that high
surface tension could be a problem in the lungs of
newborn babies and postulated that ‘the addition of
surface active substances to the air or oxygen which
is being spontaneously breathed in or introduced by
a respirator might aid in relieving the initial atelec-
tasis of newborn infants’ [1].
The validity of this concept was ¢rst demonstrated
in preterm newborn rabbits, lambs and monkeys (for
review, see Robertson, 1995 [2]). The clinical era of
surfactant replacement opened with the pilot study
by Fujiwara et al. [3], showing dramatic improve-
ment of lung function in babies with RDS treated
with a large dose of modi¢ed natural surfactant in-
stilled directly into the airways. Fujiwara’s data were
sensational, especially as previous attempts to treat
babies with RDS using aerosolized arti¢cial surfac-
tant had been unsuccessful. In retrospect, it is easy to
understand why these pioneering investigators came
to di¡erent conclusions. Dipalmitoylphosphatidyl-
choline (DPPC), used in the ¢rst clinical trials in
the 1960s, is no doubt an essential component of
pulmonary surfactant but cannot be used alone as
an e¡ective surfactant substitute. We now know
that hydrophobic proteins (or protein analogues)
are required to enhance spreading of the surface ac-
tive material in the airspaces. Furthermore, although
aerosolization of surfactant is technically feasible, a
more dramatic therapeutic response is usually ob-
tained by administering the exogenous material as a
bolus into the central airways.
BBADIS 61784 2-11-98
B. Robertson, H.L. Halliday / Biochimica et Biophysica Acta 1408 (1998) 346^361 347
The controversies generated by early investigators
in the ¢eld illustrate some basic problems that need
to be addressed in the design of e¡ective surfactant
substitutes and strategies for their use in clinical
practice. In the present review, we will discuss the
functional roles of various surfactant components,
dose requirements in relation to pool sizes of alveolar
surfactant in health and disease, the problem of sur-
factant inactivation in airspaces £ooded with pro-
teinaceous edema, recycling and ‘activation’ of sub-
optimal exogenous surfactants by recombination
with endogenous material, and possible interactions
between surfactant components, phagocytes, and
various pathogenic microorganisms. We will also
provide a brief overview of clinical trials and areas
of future development, as well as socioeconomic
aspects of the use of surfactant in newborn babies
and older patients.
2. Basic considerations
2.1. Functional roles of surfactant components
From its site of synthesis and storage in the alveo-
lar type II cells, natural surfactant reaches its site of
action at the air-liquid interfaces of the lung through
a series of transformations including swelling of se-
creted lamellar bodies to tubular myelin, a liquid
crystalline phase probably representing material
ready for surface adsorption. Continuity between
tubular myelin and the surface ¢lm can be demon-
strated by electron microscopy, supporting this con-
cept. The aggregation of surface active phospholipids
in the form of tubular myelin apparently requires the
presence of surfactant proteins A and B (SP-A,
SP-B) and calcium, but the exact mechanisms by
which the surfactant proteins enhance formation
and stability of the surface ¢lm remain to be eluci-
dated. Under in-vitro conditions, each of the proteins
SP-A, SP-B and SP-C accelerate adsorption of
DPPC to an air-liquid interface, and synergistic ef-
fects of these proteins have been described (for re-
view, see [4] and chapter by Perez-Gil and Keough,
this volume). Although the ¢lm separating the gas
and liquid phases at the alveolar surface is usually
described as a monolayer, there is evidence from
both ultrastuctural and biophysical studies that mul-
tilayers of surfactant material are present at the air-
liquid interface (Fig. 1). These multilayers could rep-
resent the surface-associated reservoir postulated by
Schu«rch and Bachofen [5] on the basis of measure-
ments of surfactant ¢lms with the captive bubble
technique (for more detailed coverage, see chapter
by Schu«rch, this volume). Subsequent steps in the
life cycle of natural surfactant probably include de-
sorption of waste material from the air-liquid inter-
face, and re-uptake and re-utilization by alveolar
type II cells (for review, see [6]).
The secretion and recycling of surfactant by alveo-
lar type II cells are regulated by feedback mecha-
nisms, probably via a membrane receptor to SP-A.
About 95% of PC is re-utilized in the neonatal rabbit
lung, but considerably less in the adult animal [6].
Clearance from the lungs is faster for surfactant pro-
teins SP-A and SP-B than for DPPC, and there is
less recycling of the protein components. It is also
well known that the structural and biophysical prop-
erties of extracellular surfactant vary at di¡erent
stages of the life cycle, from presumably newly se-
creted highly surface active ‘large aggregates’ rich in
tubular myelin, to less active ‘small aggregates’ of
vesicular material containing less protein and prob-
ably representing material heading for recycling (for
Fig. 1. Electron microphotograph of alveolar lining layer in a
fullterm newborn rabbit (age 6 h), illustrating the concept of a
surface-associated surfactant reservoir. Surfactant material is
present as secreted lamellar bodies, tubular myelin, and a sur-
face ¢lm that seems to be multilamellar. The thickness of the
surface ¢lm is 16^18 nm, corresponding to at least 4 tightly
packed bilayers of phospholipids. Lead citrate, uranyl acetate,
U39 000.
BBADIS 61784 2-11-98
B. Robertson, H.L. Halliday / Biochimica et Biophysica Acta 1408 (1998) 346^361348
details, see chapter by Ikegami and Jobe, this vol-
ume).
As outlined above, the life cycle of natural surfac-
tant is driven by a complex and probably tightly
regulated machinery ensuring, under normal condi-
tions, adequate supply of surfactant material at the
air-liquid interfaces of the lung, and at the same time
avoiding potentially harmful accumulation of lipo-
proteinaceous material in the airspaces. However,
the important point to be made in this context is
that an exogenous surfactant for clinical use may
serve its purpose without following all the rules of
the game for natural surfactant. Most of the cur-
rently used commercially available modi¢ed natural
surfactant substitutes are isolated from animal lungs
by a series of steps including extraction with organic
solvents. This puri¢cation procedure removes the hy-
drophilic proteins SP-A and SP-D, leaving a material
containing only lipids and small amounts of hydro-
phobic proteins. A preparation like Curosurf0
(Chiesi Farmaceutici, Parma, Italy), which is further
puri¢ed by liquid-gel chromatography, contains only
polar lipids and about 1% hydrophobic proteins (SP-
B and SP-C in an approximate molar ratio of 1:2).
Such ‘lipid extract’ surfactants cannot generate tub-
ular myelin but nevertheless they adsorb rapidly to
an air-liquid interface, spread e¡ectively in the air-
spaces and are physiologically active both in animal
models of surfactant de¢ciency and in clinical prac-
tice (for review, see [7]). Blocking of SP-A in exoge-
nous natural surfactant with a monoclonal antibody
does not seem to destroy its physiological e¡ect in
surfactant de¢cient newborn animals whereas block-
ing of SP-B under similar experimental conditions
causes serious impairment of surfactant function [8].
DPPC is almost certainly an essential component
of exogenous surfactant but, as mentioned above, it
cannot be used alone as a surfactant substitute sim-
ply because it has a solid-to-liquid gel transition tem-
perature of 41‡C and therefore does not spread in the
lungs at normal body temperature. Some agent(s)
facilitating surface spreading must be present, such
as the complex mixture of unsaturated phospholip-
ids, neutral lipids including cholesterol, and speci¢c
proteins found in natural surfactant. Unsaturated
phosphatidylglycerol (PG) is the only component be-
sides DPPC in the arti¢cial surfactant ALEC0 (Pu-
mactant, Britannia Pharmaceuticals, Redhill, Surrey,
UK). Spreading of surfactant lipids may also be
achieved by addition of non-natural products. In
the arti¢cial surfactant, Exosurf0 (Burroughs Well-
come, Research Triangle Park, NC, USA), spreading
of DPPC is promoted by addition of hexadecanol
(cetyl alcohol) and tyloxapol. Both ALEC0 and
Exosurf0 have a slow action compared to protein-
containing modi¢ed natural surfactants, and it seems
likely that these protein-free preparations, at least to
some extent, exert their e¡ects by serving as sub-
strates for the recycling machinery in type II cells.
Extensive systematic studies were performed by
Tanaka et al. [9] in order to identify an ideal mixture
of synthetic lipids which together with native hydro-
phobic proteins would constitute an optimal surfac-
tant substitute. On the basis of surface tension meas-
urements with a Wilhelmy balance and static
pressure-volume recordings in premature newborn
rabbits treated with a variety of lipid-protein combi-
nations they concluded that a mixture of DPPC, un-
saturated PG, and palmitic acid (68:22:9, by weight)
would be suitable for this purpose. Among the two
hydrophobic proteins, SP-B seems to be a stronger
promoter of surface adsorption than SP-C [10], but
both proteins (or analogues of these proteins) may be
required to make an e¡ective arti¢cial exogenous sur-
factant. Palmitic acid, which is cleared from the air-
spaces within a few minutes of administration, prob-
ably does not in£uence the long-term stability of the
surfactant ¢lm, but may accelerate initial adsorption
and spreading. Cholesterol was identi¢ed as a poten-
tial spreading agent in exogenous surfactant more
than 20 years ago. However, as pointed out above,
a surfactant prepared from animal lungs by extrac-
tion with chloroform/methanol and subsequent re-
¢nement by liquid-gel chromatography may be
highly active although cholesterol and other neutral
lipids have been removed by the isolation procedure.
2.2. Pool sizes of surfactant and dose requirements
Dose requirements for surfactant therapy depend
on the condition being treated, e.g. on whether the
exogenous material is given to compensate for pri-
mary surfactant de¢ciency in a newborn baby, or
administered to overcome the inhibitory e¡ects of
aspirated meconium or plasma proteins leaking into
the airspaces in a patient with ARDS. The dose re-
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quired for a clinical response probably also varies
with the quality of the surfactant, depending on
how much of the material is ‘ready for use’, i.e.
present as aggregates immediately available for sur-
face adsorption. Addition of SP-A seems to increase
dose-e⁄ciency of modi¢ed natural surfactants iso-
lated by extraction with organic solvents, in part by
increasing resistance to inactivation [11]. However, as
pointed out above, SP-A is not essential for the clin-
ical e¡ect, because a high sensitivity to inactivation
can be partly counterbalanced by increasing the dose
of surfactant. Furthermore, if the damage to the al-
veolar epithelium is not too extensive, an exogenous
surfactant may become ‘activated’ by entering the
recycling machinery, to reappear in the alveolar
spaces as newly secreted ‘large aggregates’ containing
endogenous SP-A [12].
Finally, requirements and time intervals for re-
treatment depend on the severity of the disease, the
size of the initial dose, and on clearance rates for the
exogenous material. These are remarkably similar for
various currently used modi¢ed natural surfactants
when measured under standardized experimental
conditions in newborn rabbits [13], but may vary in
di¡erent clinical situations depending on the type of
lung injury and possible activation of macrophages
(which normally play a minor role in the clearance of
surfactant lipids from the airspaces) and other cata-
bolic pathways. Hallman et al. [14] studied clearance
rates for exogenous surfactant components in a few
babies with RDS, and found that the apparent half-
lives were shorter for SP-A (9 h) than for PG (33 h)
and DPPC (50 h). Taken together, all these factors
indicate that the fate and utilization of exogenous
surfactant rely upon complex interactions between
the material delivered into the lungs and the host
cells in the alveolar compartment.
The estimated pool size of ‘alveolar’ surfactant in
the normal neonatal lung (about 100 mg/kg) [15] is
much larger than the amount required to coat the
inside of the airspaces with a monolayer of surfac-
tant phospholipids (about 3 mg/kg). To some extent
this may represent a safety margin for the lung dur-
ing the critical ¢rst minutes of neonatal adaptation,
when substantial amounts of unresorbed fetal lung
liquid still remain in the airspaces. It probably also
re£ects the fact that much of the intraalveolar sur-
factant is allocated to compartments other than the
surface ¢lm, representing various phases of the dy-
namic life cycle described above, and that the surface
¢lm in many places appears to be a multilayer (Fig.
1). In order to be e¡ective for a longer period of
time, the exogenous surfactant must not only provide
a surface ¢lm with very low compressibility, but also
fuel the metabolic pathways for recycling.
The pool size of endogenous alveolar surfactant in
Fig. 2. Tidal volume at insu¥ation pressure 25 cm H2O (A),
and end-expiratory lung gas volume (B) in immature newborn
rabbits (gestational age 27 days), treated at birth with various
doses of porcine surfactant (Curosurf0). The measurements
were obtained after 30 min of mechanical ventilation. Both vol-
ume parameters increase with increasing doses of surfactant.
Bars represent means and S.E.M. a: P vs. untreated 6 0.05; b:
P vs. 200 and 300 mg/kg 6 0.05. (Based on unpublished data,
kindly provided by S. Bongrani and M. Fornasier, Parma.)
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babies with RDS is only about 10% of that in the
normal fullterm neonatal lung [16]. The mission of
exogenous surfactant when used for treatment of
RDS is to make up for this de¢cit, and the initial
dose levels recommended for currently used exoge-
nous surfactants are accordingly large, ranging from
50 to 200 mg/kg [7]. The dose has to be generous, not
only for the reasons given above, but also to com-
pensate for possible uneven distribution of the exog-
enous material and to overcome inhibitory e¡ects
caused by vascular-to-alveolar leakage of plasma
proteins in the immature lung.
Physiological e¡ects of various doses of lipid-ex-
tract surfactants have been evaluated in immature
newborn rabbits. With rabbit lung surfactant extract
administered at a standard dose volume of 25 Wl,
there was a gradual improvement of static pressure-
volume properties when the concentration of surfac-
tant was increased stepwise from 0 to 50 mg/ml, with
no further improvement at higher concentrations
[17]. With Alveofact0 (Thomae, Biberach, Ger-
many), a bovine surfactant, tidal volumes during me-
chanical ventilation with an insu¥ation pressure of
25 cm H2O increased from 6 1 ml/kg in non-treated
controls to about 6 ml/kg at a dose of 80 mg/kg [18].
With porcine surfactant (Curosurf0), both tidal vol-
ume at insu¥ation pressure 25 cm H2O and end-
expiratory lung gas volume increased in a similar
dose-dependent manner, up to about 25 ml/kg and
9 ml/kg, respectively, in animals receiving a dose of
300 mg/kg (Fig. 2). Various dose levels have also
been tested in randomized clinical trials, and the re-
sults are basically in agreement with the experimental
¢ndings summarized above. In babies with RDS, the
initial dose of exogenous surfactant should probably
be at least 100 mg/kg (see Section 3.1).
2.3. Ventilation patterns and timing of therapy
The physiological e¡ects of exogenous surfactants
in ventilated surfactant-de¢cient lungs may depend
on the use of positive end-expiratory pressure
(PEEP). The requirement of PEEP is di¡erent for
exogenous surfactants with or without SP-A [19]
and varies between di¡erent types of lipid extract
surfactants, basically re£ecting the quality of the
preparation. In clinical practice this di¡erence may
not be apparent since, in most neonatal units, ven-
tilation with PEEP is part of the routine manage-
ment of infants who need surfactant therapy. How-
ever, in experiments designed to compare the in-vivo
e¡ects of various surfactant preparations, ventilator
settings must be carefully standardized to allow
meaningful interpretation of the data. Combined
use of exogenous surfactant and high frequency ven-
tilation (HFV), which inevitably implies the use of a
comparatively high continuous distending airway
pressure, may also be bene¢cial. In a recent study
on adult rats with experimental meconium aspira-
tion, we found that animals subjected to HFV after
treatment with surfactant were better oxygenated
than animals undergoing conventional ventilation
(Calkovska¤, A., Sun, B., Curstedt, T., Renheim, G.
and Robertson, B., unpublished data). Regardless of
the type of ventilatory support, the important issue is
to keep the lung open at end-expiration, avoiding
harmful mechanical stress caused by repeated col-
lapse and re-expansion of terminal airspaces.
Treatment e¡ects may also vary with the ‘ventila-
tion history’ of the lungs. Epithelial disruption oc-
curs very quickly after onset of ventilation in a sur-
factant de¢cient neonatal lung and leakage of plasma
proteins from denuded surfaces in airways and alveo-
li may compromise the e¡ect of subsequent treatment
with surfactant. In a recent series of experiments on
immature newborn lambs, we found that animals
who had been subjected to a brief period of manual
ventilation with large tidal volumes (35^40 ml/kg) at
birth failed to respond adequately to surfactant ther-
apy given 30 min later. These non-responders had
poorly aerated parenchyma and widespread lung
injury with airway epithelial necrosis, hyaline mem-
branes and recruitment of granulocytes to the air-
spaces, in contrast to the well expanded parenchyma
of control animals treated with surfactant at birth
without being subjected to the hyperventilation ma-
neuver [20]. Our observations are in agreement with
data recently reported by Wada et al. [21], who like-
wise found that ventilation with large tidal volumes
(20 ml/kg) reduced the bene¢ts of subsequent surfac-
tant therapy in immature newborn lambs.
In experiments on near-term newborn rabbits with
surfactant dysfunction induced by tracheal instilla-
tion of lysophosphatidylcholine (lyso-PC) soon after
delivery, we noted that animals treated with exoge-
nous surfactant 30 min later failed to respond. These
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animals also had a much larger leakage of albumin
into the airspaces than animals receiving supplemen-
tary surfactant together with lyso-PC at birth, and
the large leak was associated with biophysical evi-
dence of surfactant inactivation (Grossmann, G., Ta-
shiro, K., Kobayashi, T., Suzuki, Y., Matsumoto,
Y., Waseda, Y., Akino, T., Curstedt, T. and Robert-
son, B., unpublished data). Timing of surfactant
therapy in relation to the degree and stage of lung
injury thus determines the response, as further illus-
trated by data from clinical trials comparing various
treatment regimens for babies with RDS (see below).
In an immature newborn animal, prophylactic ad-
ministration of surfactant before onset of breathing
has a better, and more longlasting, e¡ect on lung
function than treatment with the same dose after
the onset of respiratory failure. To some extent,
this di¡erence can be explained by the fact that the
exogenous surfactant is distributed more uniformly
when instilled into the liquid-¢lled airways at birth.
High doses of surfactant may be required to over-
come inhibitory e¡ects in babies aspirating meco-
nium, although these infants are usually more mature
than those with RDS and therefore should have a
larger pool of endogenous surfactant. The inhibitory
e¡ect of meconium on surfactant does not simply
re£ect the stoichiometric relation between the two
factors. Measurements with a pulsating bubble have
revealed that a suspension of lipid extract surfactant
at a concentration of 1.5 mg/ml is almost completely
inactivated by meconium at a concentration of 65 Wg/
ml. If the concentration of surfactant is raised two-
fold, i.e. to 3 mg/ml, 20 times more meconium is
required to elicit the same inhibitory e¡ect [22]. In
other words, increasing the concentration makes the
surfactant relatively more resistant to inactivation.
This important observation provides a rationale for
the therapeutic use of surfactant in infants with
MAS.
2.4. Modes of surfactant administration
The e¡ect of an exogenous surfactant is in£uenced
by the mode of administration. It has been clearly
demonstrated in experiments on lung-lavaged adult
rabbits that a bolus of surfactant suspension, rapidly
instilled via a tracheal cannula, is more evenly dis-
tributed and promotes gas exchange more e¡ectively
than the same dose of surfactant administered by
very slow (over 45 min) airway infusion [23]. Divid-
ing the dose for directed instillation into lobar bron-
chi does not seem to enhance the therapeutic e¡ect.
Several years ago, Morley et al. [24] introduced the
idea that exogenous surfactant would spread most
readily in the airspaces when administered in dry
form, but this concept was never supported by sound
experimental evidence and is not widely accepted.
However, one recent study showed improved survival
of spontaneously breathing preterm newborn rabbits,
primed with an oropharyngeal dose of surfactant at
birth and then receiving aerosolized dried natural
surfactant, administered via a treatment chamber
[25]. Further research is needed to evaluate the po-
tential of this alternative technique for delivery of
exogenous surfactant.
Nebulized liquid natural surfactant clearly im-
proves gas exchange in immature newborn [26] and
surfactant-depleted adult experimental animals (e.g.,
[27,28]). The main problem with this approach is to
avoid losses of precious surfactant suspension in the
delivery system of the ventilator or gas supply equip-
ment [29]. We have observed signi¢cant improvement
of oxygenation in ventilated lung-lavaged adult rats,
treated with aerosolized porcine surfactant for
90 min, although only about 1% of the aerosolized
material could be recovered from the airspaces at the
end of the experiment (Bahlmann, H., Sun, B., Nils-
son, G., Curstedt, T. and Robertson, B., unpublished
data). For these studies, the aerosol was generated by
a jet nebulizer, and delivery to the lungs was in-
creased by diluting the surfactant to 20 mg/ml and
by intermittent ‘rinsing’ of the aerosolization cham-
ber with saline. In this experimental model, the ther-
apeutic e¡ect of the aerosolized surfactant was
clearly inferior to that obtained with conventional
bolus administration, as previously shown by Li et
al. [28]. On the other hand, inhaled aerosolized sur-
factant seems to be more dose-e¡ective than surfac-
tant administered by airway instillation when com-
parisons are based on the amount of material
actually being deposited in the lungs [26,27]. This
would suggest selective delivery of highly active sur-
factant by aerosolization, or improved distribution.
More experimental work is required to clarify this
issue.
Cosmi et al. [30] recently reported a series of ¢ve
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preterm babies, treated with surfactant before birth.
All these babies had immature lungs as indicated by
negative shake test on amniotic £uid, and their gesta-
tional ages ranged from 28 to 32 weeks. Surfactant
was instilled during amniocentesis with the needle
placed close to the mouth of the fetus. To enhance
spreading of the instilled material into the liquid
¢lled airways, fetal breathing was induced by intra-
venous administration of aminophylline to the moth-
er. The whole procedure was monitored with ultra-
sound, and it could be shown that the exogenous
material indeed entered the fetal airways. The babies
were born by cesarean section soon after the inter-
vention. Only one of them developed RDS, and in
the other four the clinical outcome was uneventful.
Although the idea of intrauterine therapy may seem
attractive, some ethical concern has been raised [31].
Also, studies on fetal rabbits and baboons have re-
vealed that very large amounts of surfactant (20^40
times the clinical dose recommended for airway in-
stillation in babies with RDS) need to be instilled
into the amniotic cavity to obtain signi¢cant physio-
logical e¡ects during the period of neonatal adapta-
tion. It will be di⁄cult to undertake randomized con-
trolled clinical trials to evaluate whether or not this
rather complex approach is superior to conventional
prophylactic airway instillation of surfactant at birth.
2.5. Interaction with phagocytes and microorganisms
Surfactant components have important roles in the
pulmonary defence system. SP-A and SP-D appa-
rently serve as opsonins, promoting aggregation of
pathogens and stimulating phagocytosis and subse-
quent intracellular killing of microorganisms (for re-
view, see [32] and chapters by Haagsman (SP-A) and
Reid (SP-D), this volume). It has also recently been
shown that ‘knockout’ newborn mice lacking the
gene for SP-A have increased susceptibility to infec-
tion with group B streptococci (GBS) [33]. (Interest-
ingly, these gene-targeted animals do not develop
other clinical symptoms of respiratory dysfunction
at birth.) Surfactant may also downregulate the pro-
duction of tumor necrosis factor K and other cyto-
kines released by in£ammatory cells in the airspaces
(for more detailed coverage, see chapter by Korfha-
gen et al., this volume). These various interactions
may be important when surfactant is used for treat-
ment of respiratory failure caused by infection. As
further discussed below, babies with neonatal pneu-
monia due to GBS may respond very favorably to
surfactant therapy, with signi¢cant improvement of
gas exchange soon after treatment, and no evidence
of adverse side e¡ects.
Studies on ventilated premature and near-term
rabbit neonates, infected at birth with a standard
dose of GBS, have shown that treatment with a por-
cine lipid extract surfactant (Curosurf0) reduced bac-
terial proliferation in lung parenchyma during a 5-h
period of mechanical ventilation [34]. Similar e¡ects
have been observed in GBS-infected newborn rabbits
treated with a synthetic surfactant (Exosurf0) [35]. In
GBS-infected preterm animals with immature lungs,
treatment with surfactant also improves lung-thorax
compliance. The preventive e¡ect of surfactant on
bacterial proliferation was even more prominent in
animals receiving combined treatment with surfac-
tant and a polyclonal antibody to the invading mi-
croorganism (Herting, E., Gan, X.Z., Rauprich, P.,
Jarstrand, C. and Robertson, B., unpublished data).
In more recent similar experiments, in which the
animals were inoculated at birth with pneumococci,
we found no therapeutic e¡ects of surfactant or anti-
body alone. However, proliferation of bacteria in
lung tissue was again clearly reduced in animals re-
ceiving combined treatment with antibody and sur-
factant (Gan, X.Z., Jarstrand, C., Herting, E., Berg-
gren P. and Robertson, B., unpublished data).
Improved lung function after surfactant treatment
has also been reported in mice with experimental
viral pneumonia or infection with Pneumocystis car-
inii (for review, see [36]). All these experimental ob-
servations suggest that neonatal pneumonia, espe-
cially when caused by GBS, may be a suitable
target for surfactant replacement, and that combined
administration of surfactant and speci¢c antibodies
may enhance the therapeutic e¡ect.
3. Clinical trials of surfactant therapy for RDS
The general principles of surfactant therapy were
developed from research in animal models but they
have been re¢ned following the results of a number
of randomized clinical trials. Studies comparing high
with low doses, early with late treatment, single with
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multiple doses and natural with synthetic surfactants
have been performed; and meta-analyses of these
trials have been reported [37,38] (Fig. 3).
3.1. Dose
In clinical trials from 25 to 200 mg phospholipids/
kg body weight have been used as single doses. For
Surfactant-TA0 120 mg/kg was more e¡ective than
60 mg/kg and for Curosurf0 an initial dose of
200 mg/kg produced better acute physiological re-
sponses than 100 mg/kg in babies with severe RDS
[39]. Other studies have shown that a multiple doses
regimen is better than giving a single dose being as-
sociated with a reduced risk of pneumothorax and
mortality. These studies used fairly rigid re-dosing
schedules every 12 h but more £exible regimens
might be more appropriate. It is likely that the
dose of phospholipids needed for prophylaxis is less
than that for treatment of RDS when inhibitory pro-
teins are present in the airspaces. For prophylaxis
100 mg/kg would seem to be an appropriate dose
of phospholipids with re-treatment after 6^12 h if
the infant remains ventilator-dependent and needs
more than 30% oxygen [40].
The total cumulative dose of surfactant needed to
Fig. 3. Overview of randomized controlled trials designed to prevent or treat respiratory distress syndrome. The diagrams illustrate
odds-ratios for various complications including mortality. Natural surfactant preparations: 8 prophylaxis trials (988 infants), 12 treat-
ment trials (1600 infants). Synthetic preparations: 7 prophylaxis trials (1477 infants), 5 treatment trials (2126 infants). Abbreviations:
PDA: persistent ductus arteriosus; IVH: intraventricular hemorrhage; BPD: bronchopulmonary dysplasia; NA: not analyzed. From
Systematic Review on Cochrane Collaboration.
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treat RDS has been studied in three trials. For
Curosurf0 a total dose of up to 300 mg/kg gave
similar long-term results as up to 600 mg/kg with
no di¡erences in mortality or oxygen dependency at
28 days [39]. In two large studies of Exosurf0 up to
4 doses (about 280 mg phospholipids/kg) were not
better than 2 doses (about 140 mg phospholipids/kg)
for the treatment of RDS [41].
3.2. Timing of ¢rst dose
Studies comparing prophylaxis and rescue treat-
ment have given con£icting results. Dunn et al. [42]
found a higher incidence of chronic lung disease at
28 days in babies treated prophylactically at birth
with a bovine surfactant compared with those treated
at a mean age of about 3 h. Merritt et al. [43] found
no di¡erences in outcome between infants treated in
the delivery room with human surfactant and those
who were treated at a mean age of about 4 h. In
contrast, Kendig et al. [44] reported a signi¢cant re-
duction in neonatal mortality in infants of less than
26 weeks’ gestation treated prophylactically with a
bovine surfactant compared to babies treated later.
In 3 trials of Curosurf0 the outcome for those
treated prophylactically (within 15 min of birth)
was better than those treated later particularly for
babies of less than 30 weeks’ gestation. A meta-anal-
ysis of these 3 trials showed a signi¢cant reduction in
neonatal mortality and severe intraventricular hem-
orrhage with prophylaxis compared to rescue treat-
ment [45].
More recently meta-analyses of all prophylaxis
versus rescue trials using natural surfactants have
been reported [38,46]. These show signi¢cant reduc-
tions in mortality and pneumothorax for prophylaxis
compared with later treatment for infants of less
than 31 weeks’ gestation. There is still a debate, how-
ever, about whether surfactant should be given im-
mediately after birth in the delivery room or some-
what later in the neonatal unit once the diagnosis of
RDS has been con¢rmed. There are no trials com-
paring prophylaxis with treatment at 1 h of age.
Perhaps the best advice is to o¡er surfactant prophy-
lactically to infants of less than 28 weeks’ gestation
and to all other preterm babies as soon as they need
endotracheal intubation either at birth or later for
respiratory distress [47].
3.3. Type of surfactant
Two quite large trials have compared the e¡ects of
treatment of RDS with Survanta0 and Exosurf0
[48,49]. Both trials showed reduced oxygen require-
ments over 72 h for babies treated with Survanta0
compared to Exosurf0. There was a signi¢cant re-
duction in the incidence of pneumothorax with
Survanta0. The trend in long-term outcomes also
favored the babies treated with the natural surfactant
but was not signi¢cant. A number of smaller studies
have also compared natural and synthetic surfactants
and meta-analyses of all these trials have been per-
formed [50,51]. The meta-analyses include about
4000 infants and demonstrate a reduced risk of pneu-
mothorax and a borderline reduced risk of neonatal
mortality in those treated with natural compared
with synthetic surfactants.
Since these di¡erences are quite small there is still
controversy over which type of surfactant should be
used in clinical practice. The choice of surfactant
may be based upon the neonatologist’s opinion of
the need for a rapid response and on the timing of
administration. Synthetic surfactants with their slow-
er response may be favored for prophylaxis whereas
natural surfactants with their rapid response may be
more suitable for very ill babies at risk of barotrau-
ma and pulmonary air leaks [40].
3.4. Other aspects of treatment
Attempts have been made to administer surfactant
without the requirement for subsequent mechanical
ventilation. Perhaps the ¢rst trial took place in Ku-
wait where a bovine surfactant, extracted with organ-
ic solvents and puri¢ed by liquid-gel chromatogra-
phy, was used to treat 14 infants with RDS of
birth weight s 1500 g under conditions where facili-
ties for mechanical ventilation were not available
[52]. After surfactant instillation these infants were
extubated and in most cases their respiratory distress
improved with 13 surviving. This intervention was
taken a stage further by Verder et al. [53] who used
nasal continuous positive airway pressure (CPAP) to
treat infants with RDS before and after surfactant
administration. In a randomized controlled trial this
procedure reduced the need for subsequent mechan-
ical ventilation by half. Use of CPAP in very imma-
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ture babies may not be e¡ective and the role of sur-
factant replacement in infants of less than 700 g birth
weight or 23 to 26 weeks’ gestational age is contro-
versial.
In a study with Exosurf0, Stevenson et al. [54]
could not ¢nd a bene¢t from treatment of infants
less than 700 g and a report from Scandinavia sug-
gested the same for infants treated with Curosurf0
[55]. However, a study from the USA suggested im-
proved survival of infants of gestational ages 23 to
26 weeks’ gestation treated with Survanta0 [56]. In-
fants of this maturity treated with natural surfactants
demonstrate acute physiological improvements in
lung function but in some cases this may not be
enough to ensure survival which may depend upon
maturity of other organ systems such as the brain,
heart and gastro-intestinal tract. Prenatal corticoste-
roids enhance fetal lung maturity and reduce both
the incidence and the severity of RDS, and there
are synergistic e¡ects when this treatment is used in
conjunction with postnatal surfactant therapy.
3.5. Clinical trials of surfactant therapy for conditions
of surfactant inactivation
Uncontrolled clinical trials have shown improved
oxygenation in babies with severe MAS treated with
bovine or porcine surfactant. One randomized trial
has been reported [57] in which babies with severe
MAS were given up to 4 doses of Survanta0, a bo-
vine surfactant in a dose of 150 mg/kg at 6 hourly
intervals. Several hours elapsed before substantial
improvement in oxygenation was seen but treated
infants had a reduced incidence of air leaks, reduced
duration of mechanical ventilation and shorter hos-
pital stay compared to control infants. Recent studies
have shown that lavage of meconium stained lungs
with natural surfactants increases the yield of meco-
nium removal. Clinical trials are currently being per-
formed to assess the usefulness of this approach in
the prevention and treatment of MAS. Improved
lung function has been observed also in term babies
with pneumonia treated with surfactant, but no con-
trolled trials have been reported.
ARDS in adults has been treated with surfactant
[58] and recently there have been two randomized
controlled trials [59,60]. Aerosolized Exosurf0 did
not improve physiological measurements of lung
function or survival in a large randomized trial of
adults with ARDS compared with placebo [59]. On
the other hand Survanta0 [60] instilled in a total dose
of 400 mg/kg (4 doses at 6 hourly intervals) was
associated with reduced oxygen requirement and
mortality. The discrepancy in outcome between these
two trials may have been due to the di¡erences be-
tween the surfactant preparations or the method of
administration both leading to ine¡ective targeting of
surfactant in the lungs. Although a number of anec-
dotal studies have reported bene¢cial e¡ects of sur-
factant treatment in infants and children with
ARDS, there have been no randomized trials.
Abnormalities of pulmonary surfactant have been
reported in infants with bronchiolitis [61]. These
amounted to a marked de¢ciency of SP-A and disa-
turated PC, both of which resolved as the disease
improved. Functional activity of surfactant from
these infants with bronchiolitis was less impaired
but there may be a potential role for exogenous sur-
factant therapy. There has been one randomized con-
trolled trial of a porcine-derived surfactant in infants
with severe bronchiolitis. There were improvements
in oxygenation and ventilator pressures from 1 and
3 h, respectively, in treated infants. All infants sur-
vived but those given surfactant had reduced time on
the ventilator and shorter hospital admission [62].
There has been one prospective randomized con-
trolled trial of Exosurf0 given by aerosol to adults
with stable chronic bronchitis [63]. This trial reported
modest improvements in pulmonary function after 14
days in patients treated with 607.5 mg of DPPC/day.
4. A note on SP-B de¢ciency
Recently ‘congenital alveolar proteinosis’ has been
shown to be due to a genetic de¢ciency of SP-B [64].
Untreated infants develop respiratory failure and die.
Prenatal diagnosis of SP-B de¢ciency in one case
allowed treatment with Survanta0 over a long period
of time but the infant died at 54 days of age [65].
SP-B replacement with natural surfactant does not
overcome the functional abnormalities so that alter-
native interventions such as lung transplantation or
gene therapy will be needed to overcome this con-
genital disorder. Partial de¢ciency of SP-B has been
reported in a term infant who developed chronic lung
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disease. He was heterogeneous for the SP-B gene and
died at the age of 15 months while awaiting lung
transplantation.
5. Socioeconomic aspects
The introduction of surfactant treatment was asso-
ciated with a general reduction in mortality for in-
fants weighing between 601 and 1300 g at birth [66]
and in the overall neonatal and infant mortality in
the USA [67]. Follow up studies have not to date
discovered any longterm adverse e¡ects of surfactant
therapy. The impact of this treatment has been seen
mainly in the developed world where respiratory dis-
tress and congenital malformations remain the major
causes of neonatal mortality. In developing countries
about 10 million preterm babies die each year and
other measures to combat infection are of more im-
portance than providing a relatively expensive ther-
apy such as surfactant.
Surfactant is an expensive therapy at about 500
US dollars a dose but in the developed world it is
very cost e¡ective [68]. The cost of surfactant, even
in multiple dose regimens, is small in comparison to
total costs of neonatal intensive care. In addition, the
costs of neonatal intensive care are relatively low
when compared to those of other medical treatments
such as hemodialysis, renal transplantation or bone
marrow transplantation. Calculations of discounted
costs per year per extra survivor after surfactant
therapy range from 600 to 1200 US dollars [68].
6. Concluding remarks
6.1. Towards a new generation of surfactant
substitutes
It seems likely that we in the near future will see
the advent of a new generation of arti¢cial substi-
tutes, competing on the market with currently avail-
able modi¢ed natural surfactants. These new prepa-
rations will probably be based on copies (or
analogues) of the surfactant associated hydrophobic
proteins, produced by recombinant technology or
protein synthesis, reconstituted with selected syn-
thetic lipids. New surfactant substitutes based on re-
combinant SP-C have been developed, and success-
fully tested in animal experiments (e.g., [69]), but not
yet reached the level of clinical use. An example of
innovative thinking is the ‘KL4’-peptide originally
described by Cochrane and Revak [70]. KL4 is a
21-residue peptide, containing repeated stretches of
one lysine and 4 leucines. This arti¢cial peptide is
physiologically active when recombined with
DPPC, PG and palmitic acid, and very promising
data have been reported from both animal experi-
ments and a non-randomized clinical trial evaluating
the KL4-surfactant for treatment of neonatal RDS
[71].
Arti¢cial surfactants based on new protein ana-
logues could perhaps be tailored for di¡erent clinical
situations, for instance by maximizing resistance to
inactivation or bacteriostatic e¡ects. The ‘reconstitu-
tion’ of an extremely hydrophobic peptide with lipids
in aqueous environment may, however, present tech-
nical problems, caused by oligomerization and con-
sequent precipitation of the protein component, pre-
venting proper biophysical function of the arti¢cial
surfactant. New protein analogs may have to be de-
veloped to solve these problems. Considering the ex-
cellent physiological properties of currently available
modi¢ed natural surfactant substitutes, it will prob-
ably be di⁄cult to demonstrate superiority of new
synthetic surfactants in clinical trials.
6.2. Possible new targets for surfactant therapy
RDS of the newborn was an almost perfect target
disease for surfactant therapy as it is characterized
by a mainly primary de¢ciency of pulmonary surfac-
tant as a result of immaturity. In many cases there
may also be surfactant inactivation due to plasma
proteins leaking into the airspaces. Many, if not
all, neonatal respiratory disorders have some element
of surfactant dysfunction and earlier in this review
we have discussed the use of surfactant to treat ba-
bies with meconium aspiration and congenital pneu-
monia. In infants, children and adults a variety of
pulmonary disorders has been subjected to studies of
surfactant therapy including ARDS, bronchiolitis
and chronic bronchitis. Surfactant treatment has
also been reported for pulmonary hypoplasia in con-
genital diaphragmatic hernia, pulmonary hemor-
rhage, infants having ECMO and chronic lung dis-
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ease (for review, see [72]). Controlled trial data are
lacking for most of these potential indications for
surfactant therapy.
In the future, surfactant treatment may come to be
an important adjunctive therapy in not only neonatal
lung disease but in pulmonary disorders of adults
and children. In principle, any lung disorder interfer-
ing with surfactant function could become a poten-
tial target for surfactant therapy. Worldwide pneu-
monia, asthma and chronic bronchitis with or
without emphysema would constitute huge numbers
of potential recipients particularly if the surfactant
could be safely and e¡ectively administered prefera-
bly as an aerosol.
Finally surfactant liposomes may prove to be an
important method of dispersion of antibiotics and
other drugs in the airways. It may also be possible
to facilitate gene therapy for cystic ¢brosis or familial
SP-B de¢ciency using surfactant liposomes as a ve-
hicle. Topical therapy with antibiotics may be more
appropriate than systemic treatment with these drugs
in situations of chronic infection such as cystic ¢b-
rosis and bronchiectasis. The full potential of surfac-
tant therapy for various forms of lung disease thus
remains to be explored, and the development of new
synthetic surfactant substitutes (eliminating the risk
of contamination with prions in products of animal
origin) is still an important challenge for future re-
search.
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